Results 41 to 50 of about 4,103,638 (290)

Drug resistance mutations in drug-naive HIV type 1 subtype C-infected individuals from rural Malawi. [PDF]

, 2010
In this preliminary study we show that in 2008, 3 years after antiretroviral therapy was introduced into the Karonga District, Malawi, a greater than expected number of drug-naive individuals have been infected with HIV-1 subtype C virus harboring major ...
Grace P. McCormack, Emmanuel Banda, Judith R. Glynn, Bansode, Vijay, McCormack, Grace P., Glynn, Judith R., Neil French, French, Neil, Glynn, Judith R, Zuzanna J. Drebert, Banda, Emmanuel, Drebert, Zuzanna J., Molesworth, Anna, Vijay Bansode, Travers, Simon AA, Amelia Crampin, Drebert, Zuzanna, McCormack, Grace P, Crampin, Amelia, Anna Molesworth, Drebert, Zuzanna J, Simon A.A. Travers, Travers, Simon A A, Travers, Simon A.A., Ngwira, Bagrey, Bagrey Ngwira   +25 more
core   +1 more source

Venetoclax‐Based Therapy as a Bridge to Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Pediatric Acute Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Relapsed and/or refractory (R/R) pediatric acute leukemia carries a dismal prognosis, largely driven by chemoresistance to conventional salvage therapy. The BH3‐mimetic venetoclax, combined with chemotherapy or hypomethylating agents, has demonstrated efficacy in small clinical trials.
Katherine S. Colman, Deborah Meyran, Vajiranee Malalasekera, Heather Weerdenburg, Janine Campbell, Rachel Conyers, Stacie Wang, Hannah Walker, Seong Lin Khaw, Diane Hanna   +9 more
wiley   +1 more source

Hepatic metastasis with heterologous rhabdomyoblastic differentiation in a patient with gastrointestinal stromal tumor treated with imatinib

Indian Journal of Pathology and Microbiology, 2013
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the intestinal tract. In patients with locally advanced and/or metastatic GIST, the introduction of tyrosine kinase inhibitor, imatinib mesylate, has transformed the ...
Mukul Vij, Susama Patra, Mohamed Rela
doaj   +1 more source

Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma

Frontiers in Oncology, 2023
Multiple Myeloma (MM) is an incurable neoplasm of mature B cells and the second most prevalent hematological malignancy worldwide. While combinations of proteasome inhibitors like bortezomib (Bz) and immunomodulators (IMiDs) like lenalinomide (Len) are ...
Antoine Domenger, Daniela Ricci, Véronique Mayau, Laleh Majlessi, Christophe Marcireau, Gilles Dadaglio, Caroline Demangel   +6 more
doaj   +1 more source

Combination of PIM and JAK2 inhibitors synergistically suppresses cell proliferation and overcomes drug resistance of myeloproliferative neoplasms

Oncotarget, 2014
Inhibitors of JAK2 kinase are emerging as an important treatment modality for myeloproliferative neoplasms (MPN). However, similar to other kinase inhibitors, resistance to JAK2 inhibitors may eventually emerge through a variety of mechanisms. Effective drug combination is one way to enhance therapeutic efficacy and combat resistance against JAK2 ...
Shih-Min A. Huang, Anlai Wang, Rita Greco, Zhifang Li, Fangxian Sun, Claude Barberis, Michel Tabart, Vinod Patel, Laurent Schio, Raelene Hurley, Bo Chen, Hong Cheng, Christoph Lengauer, Jack Pollard, James Watters, Carlos Garcia-Echeverria, Dmitri Wiederschain, Francisco Adrian, JingXin Zhang   +18 more
openaire   +3 more sources

Evidence‐Based Clinical Practice Guidelines for the Management of Pediatric Febrile Neutropenia: Resource‐Sensitive Recommendations for the Asian Continent

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Febrile neutropenia (FN) is a frequent and serious complication in children receiving cancer therapy. Standardizing FN management across Asia is challenging due to variable healthcare infrastructure, diagnostic capacity, and infection patterns; however, it could improve resource use and patient outcomes.
Joliza Patricia Cañeba, Shweta Bansal, Tea Reljic, Allyne Montecillo‐Aguelo, Hamidah Alias, Farrah Amaranto, Maria Stella Aquino‐Calingasan, Bambang Ardianto, Eggi Arguni, Sally Blair, Thi Tam Dang, Maria Beatriz Gepte, Samanmalee Gunasekara, Andini Handayani, Miriam Kimpo, Catherine G. Lam, Nawachai Lertvivatpong, Sergio Licona, Ana Loseo, Ratha Mlis, Vivian Moreno Berrio, Nguyen Hoai Anh, Anna Lisa Ong‐Lim, Ha Thu Pham, Krishna Sagar Sharma, Bun Sereyleak, Sally Jane G. Velasco‐Aro, Su Yadana, Ambuj Kumar, Sheena Mukkada   +29 more
wiley   +1 more source

_M. tuberculosis_ interactome analysis unravels potential pathways to drug resistance [PDF]

, 2008
Drug resistance is a major problem for combating tuberculosis. Lack of understanding of how resistance emerges in bacteria upon drug treatment limits our ability to counter resistance.
Nagasuma Chandra, Karthik Raman
core  

Safety of Daprodustat for the Treatment of Chronic Kidney Disease Anemia: Final Analysis of a Multicenter Postmarketing Surveillance Study in Japan

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction This final analysis of a multicenter, prospective postmarketing surveillance study evaluated the safety of daprodustat in patients with chronic kidney disease anemia in routine clinical practice in Japan. Methods Patients who initiated daprodustat between September 2020 and July 2022 were registered.
Tadao Akizawa, Kyomi Kanaya, Kiyomi Aizawa, Masanori Onoki, Hirofumi Ozeki, Kazuko Suzuki, Ai Hayashi, Tomohiko Asamura   +7 more
wiley   +1 more source

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Modelling the impact of intermittent preventive treatment for malaria on selection pressure for drug resistance. [PDF]

, 2007
BACKGROUND\ud \ud Intermittent preventive treatment (IPT) is a promising intervention for malaria control, although there are concerns about its impact on drug resistance.\ud \ud METHODS\ud \ud The key model inputs are age-specific values for a) baseline
Sutherland Colin, Schellenberg, David, Roper, C., Schellenberg, D., Roper Cally, Roper, Cally, Sutherland, C., Cissé, Badara, Alexander, N., Alexander Neal, Sutherland, Colin, Schellenberg David, Cissé Badara, Alexander, Neal   +13 more
core   +1 more source